337 related articles for article (PubMed ID: 37501530)
1. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
van de Donk NWCJ; O'Neill C; de Ruijter MEM; Verkleij CPM; Zweegman S
Curr Opin Oncol; 2023 Nov; 35(6):601-611. PubMed ID: 37501530
[TBL] [Abstract][Full Text] [Related]
2. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.
Hosny M; Verkleij CPM; van der Schans J; Frerichs KA; Mutis T; Zweegman S; van de Donk NWCJ
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640611
[TBL] [Abstract][Full Text] [Related]
3. T-cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions.
O'Neill C; van de Donk NWCJ
EJHaem; 2023 Aug; 4(3):811-822. PubMed ID: 37601851
[TBL] [Abstract][Full Text] [Related]
4. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
6. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
7. Targeting GPRC5D in multiple myeloma.
Elemian S; Al Hadidi S
Expert Rev Anticancer Ther; 2024 May; 24(5):229-238. PubMed ID: 38607646
[TBL] [Abstract][Full Text] [Related]
8. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
Verkleij CPM; Frerichs KA; Broekmans M; Absalah S; Maas-Bosman PWC; Kruyswijk S; Nijhof IS; Mutis T; Zweegman S; van de Donk NWCJ
Oncotarget; 2020 Nov; 11(45):4076-4081. PubMed ID: 33227097
[TBL] [Abstract][Full Text] [Related]
9. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
Shirouchi Y; Maruyama D
Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
[TBL] [Abstract][Full Text] [Related]
10. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
11. Integrating Immune Therapies for the Treatment of Multiple Myeloma.
Mikkilineni L; Sidana S
J Natl Compr Canc Netw; 2023 Dec; 21(12):1303-1311. PubMed ID: 38081142
[TBL] [Abstract][Full Text] [Related]
12. T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma.
Verkleij CPM; O'Neill CA; Broekmans MEC; Frerichs KA; Bruins WSC; Duetz C; Kruyswijk S; Baglio SR; Skerget S; Montes de Oca R; Zweegman S; Verona RI; Mutis T; van de Donk NWCJ
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38687588
[TBL] [Abstract][Full Text] [Related]
13. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
Kazandjian D; Kowalski A; Landgren O
Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
[TBL] [Abstract][Full Text] [Related]
14. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
15. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; RodrÃguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A
N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686
[TBL] [Abstract][Full Text] [Related]
16. Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents.
Del Giudice ML; Galimberti S; Buda G
Cancer Immunol Immunother; 2023 Dec; 72(12):3931-3937. PubMed ID: 37924369
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.
Wang X; Zhao A; Zhu J; Niu T
Front Immunol; 2024; 15():1348955. PubMed ID: 38482019
[TBL] [Abstract][Full Text] [Related]
18. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
[TBL] [Abstract][Full Text] [Related]
19. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
Mazahreh F; Mazahreh L; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy JD; Zhan F; van Rhee F; Al Hadidi S
Blood Adv; 2023 Jul; 7(13):3069-3074. PubMed ID: 36857755
[TBL] [Abstract][Full Text] [Related]
20. Options at the time of relapse after anti-BCMA therapy.
Razzo B; Garfall AL; Cohen AD
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):450-458. PubMed ID: 38066864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]